IRIDEX Corporation
As of Oct 22, 2026, IRIDEX is in Stage 4, the downtrend phase, now in week 13 (since Jul 28, 2026). It closed at $0.76, 51.3% below its 52-week high and below its 200-day average, which is falling.
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IRIX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IRIX among Medical Devices71st of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …71 | IRIX | Stage 4 · wk 13 | 33 | +20.6% |
IRIDEX: quick answers
What stage is IRIDEX in?
As of Oct 22, 2026, IRIDEX (IRIX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 28, 2026 and is in week 13. What the four stages mean
Is IRIDEX in an uptrend?
No. IRIDEX is in a Stage 4 downtrend. It trades 28.0% below its 200-day average, which is falling.
How far is IRIDEX from its 52-week high?
IRIDEX closed at $0.76 on Oct 22, 2026, 51.3% below its 52-week high of $1.56. Its 52-week low is $0.61.
How has IRIDEX performed over the past year?
As of Oct 22, 2026, IRIDEX is down 29.6% over the past year and down 35.0% so far in 2026.
Which sector and industry is IRIDEX in?
IRIDEX is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.